

The invention relates to a method for diagnosing and
5 treating Hodgkin's lymphomas (lymphogranulomatosis) which
is based on the expression of the variant exon v10 of the
CD44 gene as a molecular marker or target. There is a
significant correlation between v10 expression and the
stage and prognosis of the disease. In a preferred
10 embodiment, v10-specific antibody molecules are used to
measure the expression of the exon in samples. In another
preferred embodiment, radiolabelled v10-specific
antibodies are used to treat Hodgkin's lymphomas.